Abstract
Background: Topical photodynamic therapy (PDT) is an excellent treatment option for actinic keratosis (AK). Pain is one of the major adverse effects. Objective: To compare the pain intensity during the extensive treatment of cosmetic units using 5-aminolaevulinic acid methylester (MAL) or 5-aminolaevulinic acid nanoemulsion (BF-200-ALA). Methods: 173 patients with 965 treated areas were enrolled in this retrospective monocentric study. All patients had multiple AKs and received an extensive treatment of the photodamaged area. 424 areas were treated with MAL and 541 with BF-200-ALA. Pain was rated using a standardized visual analogue scale (VAS). The number of PDT treatment interruptions was documented. Results: PDT with MAL led to a lower mean VAS score (5.0 vs. 5.8), a lower number of treatment interruptions (13.2 vs. 19.9%) and a lower amount of patients experiencing severe pain (25.0 vs. 36.0%) compared to PDT with BF-200-ALA. Conclusion: Our data shows that PDT using MAL is less painful than PDT using BF-200-ALA resulting in a significantly lower mean VAS score (p < 0.001), significantly fewer patients experiencing severe pain (p < 0.001) and a significantly (p < 0.05) lower number of treatment interruptions. Differences in selectivity for tumour cells and transport of ALA in peripheral neurons may play a role.
Journal Section:
Original Paper
References
1.
Morton CA, McKenna KE, Rhodes LE: Guidelines for topical photodynamic therapy: update. Br J Dermatol 2008;159:1245–1266.
[PubMed]
2.
Gholam P, Denk K, Sehr T, Enk A, Hartmann M: Factors influencing pain intensity during topical photodynamic therapy of complete cosmetic units for actinic keratoses. J Am Acad Dermatol 2010;63:213–218.
3.
Miller I, Nielsen J, Lophaven S, Jemec G: Factors related to pain during routine photodynamic therapy: a descriptive study of 301 patients. J Eur Acad Dermatol Venereol 2011, E-pub head of print.
4.
Grapengiesser S, Ericson M, Gudmundsson F, Larko O, Rosen A, Wennberg AM: Pain caused by photodynamic therapy of skin cancer. Clin Exp Dermatol 2002;27:493–497.
[PubMed]
5.
Sandberg C, Stenquist B, Rosdahl I, Ros AM, Synnerstad I, Karlsson M, Gudmundson F, Ericson MB, Larko O, Wennberg AM: Important factors for pain during photodynamic therapy for actinic keratosis. Acta Derm Venereol 2006;86:404–408.
6.
Wiegell SR, Skiveren J, Philipsen PA, Wulf HC: Pain during photodynamic therapy is associated with protoporphyrin IX fluorescence and fluence rate. Br J Dermatol 2008;158:727–733.
7.
Babilas P, Knobler R, Hummel S, Gottschaller C, Maisch T, Koller M, Landthaler M, Szeimies RM: Variable pulsed light is less painful than light-emitting diodes for topical photodynamic therapy of actinic keratosis: a prospective randomized controlled trial. Br J Dermatol 2007;157:111–117.
8.
Babilas P, Kohl E, Maisch T, Backer H, Gross B, Branzan AL, Baumler W, Landthaler M, Karrer S, Szeimies RM: In vitro and in vivo comparison of two different light sources for topical photodynamic therapy. Br J Dermatol 2006;154:712–718.
9.
Babilas P, Travnik R, Werner A, Landthaler M, Szeimies RM: Split-face-study using two different light sources for topical PDT of actinic keratoses: non-inferiority of the LED system. J Dtsch Dermatol Ges 2008;6:25–32.
10.
Kasche A, Luderschmidt S, Ring J, Hein R: Photodynamic therapy induces less pain in patients treated with methyl aminolevulinate compared to aminolevulinic acid. J Drugs Dermatol 2006;5:353–356.
11.
Wiegell SR, Stender IM, Na R, Wulf HC: Pain associated with photodynamic therapy using 5-aminolevulinic acid or 5-aminolevulinic acid methylester on tape-stripped normal skin. Arch Dermatol 2003;139:1173–1177.
12.
Maisch T, Santarelli F, Schreml S, Babilas P, Szeimies RM: Fluorescence induction of protoporphyrin IX by a new 5-aminolevulinic acid nanoemulsion used for photodynamic therapy in a full-thickness ex vivo skin model. Exp Dermatol 2010;19:e302–e305.
13.
Jemec GB: A simple method for routine measure of photodynamic therapy-associated pain. Photodermatol Photoimmunol Photomed 2010;26:51–52.
14.
Moloney FJ, Collins P: Randomized, double-blind, prospective study to compare topical 5-aminolaevulinic acid methylester with topical 5-aminolaevulinic acid photodynamic therapy for extensive scalp actinic keratosis. Br J Dermatol 2007;157:87–91.
15.
Rud E, Gederaas O, Hogset A, Berg K: 5-Aminolevulinic acid, but not 5-aminolevulinic acid esters, is transported into adenocarcinoma cells by system BETA transporters. Photochem Photobiol 2000;71:640–647.
[PubMed]
16.
Peng Q, Soler AM, Warloe T, Nesland JM, Giercksky KE: Selective distribution of porphyrins in skin thick basal cell carcinoma after topical application of methyl 5-aminolevulinate. J Photochem Photobiol B 2001;62:140–145.
[PubMed]
17.
Peng Q, Warloe T, Moan J, Heyerdahl H, Steen HB, Nesland JM, Giercksky KE: Distribution of 5-aminolevulinic acid-induced porphyrins in noduloulcerative basal cell carcinoma. Photochem Photobiol 1995;62:906–913.
[PubMed]
18.
Ahmadi S, McCarron PA, Donnelly RF, Woolfson AD, McKenna K: Evaluation of the penetration of 5-aminolevulinic acid through basal cell carcinoma: a pilot study. Exp Dermatol 2004;13:445–451.
19.
Fritsch C, Homey B, Stahl W, Lehmann P, Ruzicka T, Sies H: Preferential relative porphyrin enrichment in solar keratoses upon topical application of delta-aminolevulinic acid methylester. Photochem Photobiol 1998;68:218–221.
20.
Szeimies RM, Radny P, Sebastian M, Borrosch F, Dirschka T, Krahn-Senftleben G, Reich K, Pabst G, Voss D, Foguet M, Gahlmann R, Lubbert H, Reinhold U: Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study. Br J Dermatol 1010;163:386–394.
© 2011 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2011
You do not currently have access to this content.
